Dr. Brahmer is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
300 Mason Lord Drive
Kimmel Cancer Center
Baltimore, MD 21224Phone+1 410-550-1711Fax+1 410-550-1116
Summary
- Dr. Julie Brahmer is an oncologist in Baltimore, MD and is affiliated with multiple hospitals in the area, including Johns Hopkins Hospital and Johns Hopkins Bayview Medical Center. She received her medical degree from University of Nebraska College of Medicine and has been in practice 24 years. She specializes in thoracic oncology and is experienced in gastrointestinal oncology, and general medical oncology.
Education & Training
- Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1997 - 2000
- University of Utah HealthResidency, Internal Medicine, 1993 - 1997
- University of Nebraska College of MedicineClass of 1993
Certifications & Licensure
- FL State Medical License 2021 - Present
- MD State Medical License 1997 - 2026
- VA State Medical License 2023 - 2026
- DC State Medical License 2022 - 2024
- PA State Medical License 2024 - 2024
- UT State Medical License 1994 - 1998
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
- Fellow (FASCO) American Society of Clinical Oncologists, 2011
Clinical Trials
- Erlotinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer Start of enrollment: 2004 Sep 01
- Broccoli Sprout Extract in Preventing Lung Cancer in Smokers Start of enrollment: 2005 Jan 01
- Gemcitabine and Carboplatin Followed by Paclitaxel in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2005 Jul 01
- Join now to see all
Publications & Presentations
PubMed
- 360 citationsSociety for immunotherapy of cancer (sitc) clinical practice guideline on immune checkpoint inhibitor-related adverse eventsJulie R. Brahmer, Hamzah Abu-Sbeih, Paolo A. Ascierto, Jill Brufsky, Laura C. Cappelli
Journal for Immunotherapy of Cancer. 2021-06-01 - 412 citationsPhase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors.Patricia LoRusso, Charles M. Rudin, Josina C. Reddy, Raoul Tibes, Glen J. Weiss
Clinical Cancer Research. 2011-04-15 - 199 citationsEpigenetic therapy inhibits metastases by disrupting premetastatic nichesZhihao Lu, Jianling Zou, Shuang Li, Michael J. Topper, Yong Tao
Nature. 2020-03-12
Journal Articles
- Immune-Related (IR)-Pneumonitis During the COVID-19 Pandemic: Multidisciplinary Recommendations for Diagnosis and ManagementJoshua E Reuss, Karthik Suresh, David Feller-Kopman, Clare Rock, Julie R Brahmer, Journal For Immunotherapy of Cancer
Lectures
- Preliminary immunogenicity, safety, and efficacy of JNJ-64041757 (JNJ-757) in non-small cell lung cancer (NSCLC): Results from two phase 1 studies.2019 ASCO Annual Meeting - 6/1/2019
- General Management of Immune-Related Toxicities Incorporating Guidelines Into Practice2018 ASCO Annual Meeting - Chicago, Illinois - 06/5/2018
- Emerging Strategies in Treatment of Non−Small-Cell Lung Cancer and Head & Neck Cancer 2012CancerNet, LLC, Atlanta, Georgia - 6/16/2012
Authored Content
- Evaluation of Health-Related Quality of Life and Symptoms in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer Treated with Nivolumab or Docetaxel in CheckMate 057September 2018
Press Mentions
- Initiative for Managing Adverse Events of Immunotherapy Leads to Clinical Practice Changes at MD AndersonApril 4th, 2023
- Cancer Research Institute Virtual Immunotherapy Patient Summit Is Now Available Free, on-DemandDecember 8th, 2022
- Long-Term Clinical Benefit with Nivolumab plus Ipilimumab Extends Beyond Treatment Discontinuation in Patients with Metastatic NSCLC, Regardless of PD-L1 ExpressionOctober 18th, 2022
- Join now to see all
Committees
- Member, Update Committee of the ASCO NSCLC Expert Panel, American Society of Clinical Oncology 2015 - Present
Professional Memberships
- Fellow
External Links
- Johns Hopkins Physicianshttp://www.hopkinsmedicine.org/julie-brahmer
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: